On Friday, Shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX), gained 11.58% to $16.19.
Celldex Therapeutics, presented mature survival data from the Company’s randomized, double-blind Phase 2 study of RINTEGA(R) (rindopepimut) in patients with EGFRvIII-positive, recurrent glioblastoma (GBM) at the 20th Annual Scientific Meeting of the Society for Neuro-Oncology (SNO). The data were presented in a podium presentation by David A. Reardon, M.D., Clinical Director, Center for Neuro-Oncology, Dana-Farber Cancer Institute; Associate Professor of Medicine, Harvard Medical School; and President of the Society for Neuro-Oncology, in addition to the lead investigator of the ReACT study. RINTEGA is an investigational EGFRvIII specific therapeutic vaccine and was granted Breakthrough Therapy Designation in February 2014. Patients with recurrent glioblastoma that express the EGFRvIII mutation typically have a worse prognosis than the overall glioblastoma population, counting poor long-term survival (median time from recurrence to death for EGFRvIII-positive patients is 8.7 months1). As formerly stated, the primary endpoint of the study, progression-free survival at six months (PFS6) has been met.
- Mature overall survival (OS) data continue to show a marked benefit [hazard ratio = 0.53 (0.32, 0.88); p=0.0137] with a long-term survival benefit clearly seen in the RINTEGA arm. In May, the Company stated a hazard ratio of 0.57 (0.33, 0.98) (p=0.0386) for OS in the study.
- Nine of 10 patients (one patient lost to follow up) on the RINTEGA arm remain alive since the Company last presented data in May contrast to only two out of five patients on the control arm.
- At two years, the survival rate for RINTEGA patients is 25% as compared to 0% for control patients in the intent to treat (ITT) population, with five patients extending beyond two years.
- Five patients in the RINTEGA arm continue survival follow-up without progression per central review, contrast to only one patient on the control arm.
- A clear advantage continues to be demonstrated across multiple, clinically important endpoints counting overall survival (OS), long-term progression-free survival (PFS), objective response rate (ORR) and need for steroids.
- 33% of patients on the RINTEGA arm who were receiving steroids at baseline were able to stop steroids for six months or longer contrast to none on the control arm.
Celldex Therapeutics, Inc., a biopharmaceutical company, develops, manufactures, and commercializes novel therapeutics for human health care in the United States. The company’s lead drug candidates comprise rindopepimut (CDX-110), a targeted immunotherapeutic in a pivotal Phase III study for the treatment of front-line glioblastoma, in addition to in Phase II study for the treatment of recurrent glioblastoma; and Glembatumumab vedotin (CDX-011), a targeted antibody-drug conjugate in a randomized Phase IIb study for the treatment of triple negative breast cancer, in addition to in Phase II study for the treatment of metastatic melanoma.
Shares of Basic Energy Services, Inc (NYSE:BAS), declined -1.36% to $3.63, during its last trading session.
Basic Energy Services, declared that its administration will be presenting at three institutional investor conferences during the first two weeks of December 2015.
Roe Patterson, President and Chief Executive Officer, is planned to present at the Cowen & Company 5th Annual Ultimate Energy Conference to be held in New York City on Tuesday, December 1 at about 4:10 p.m. Eastern Time (3:10 p.m. Central Time). Mr. Patterson is also planned to present at the Capital One Securities 10th Annual Energy Conference to be held in New Orleans, Louisiana on Wednesday, December 9 at about 10:40 a.m. Central Time (11:40 a.m. Eastern Time).
Alan Krenek, Senior Vice President and Chief Financial Officer, is planned to present at the 2015 Bank of America Merrill Lynch Leveraged Finance Conference in Boca Raton, Florida on Wednesday, December 2 at about 4:40 p.m. Eastern Time (3:40 p.m. Central Time).
Basic Energy Services, Inc. provides well site services to oil and natural gas drilling and producing companies in the United States. Its Completion and Remedial Services segment offers pumping services, such as cementing, acidizing, fracturing, nitrogen, and pressure testing; rental and fishing tools; coiled tubing; snubbing services; thru-tubing; cased-hole wireline services; and underbalanced drilling in low pressure and fluid sensitive reservoirs.
Finally, Shares of United Community Banks, Inc. (NASDAQ:UCBI), ended its last trade with 0.05% gain, and closed at $20.83.
United Community Banks, declared the sale of an aggregate of 3,000,000 voting shares of United’s common stock by its largest shareholder, Corsair Capital LLC (“Corsair”), to Morgan Stanley & Co., LLC. as the sole underwriter in the registered public offering of those shares. Corsair will receive all of the net proceeds from this offering. After the sale, Corsair will hold 3,273,323 voting shares, or about 4.9% percent, of United’s outstanding voting shares, and 4,026,724 non-voting shares, or about 76.2% percent, of United’s outstanding non-voting shares. In total, Corsair will hold 7,300,047 shares, or about 10.2% percent, of United’s total outstanding shares of common stock. No shares are being sold by United.
United has filed a registration statement, counting a prospectus, and a prospectus supplement with the U.S. Securities and Exchange Commission (the “SEC”) for the offering to which this communication relates, which registration statement is effective. Before you invest, you should read the prospectus in that registration statement, the prospectus supplement and other documents United has filed with the SEC for more complete information about United and this offering. You may get these documents for free by visiting EDGAR on the SEC’s website at www.sec.gov. Alternatively, copies of the prospectus and prospectus supplement may be obtained from Morgan Stanley & Co. LLC, 180 Varick Street, 2nd Floor, New York, NY 10014.
United Community Banks, Inc. operates as the bank holding company for United Community Bank that provides retail and corporate banking services to individuals and businesses. It offers various deposit accounts, such as checking accounts, savings and time deposits, demand deposits, NOW accounts, and money market accounts.